A Natural Product Telomerase Activator As Part of a Health Maintenance Program
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Most human cells lack sufficient telomerase to maintain telomeres, hence these genetic elements shorten with time and stress, contributing to aging and disease. In January, 2007, a commercial health maintenance program, PattonProtocol-1, was launched that included a natural product-derived telomerase activator (TA-65 ® , 10–50 mg daily), a comprehensive dietary supplement pack, and physician counseling/laboratory tests at baseline and every 3–6 months thereafter. We report here analysis of the first year of data focusing on the immune system. Low nanomolar levels of TA-65 ® moderately activated telomerase in human keratinocytes, fibroblasts, and immune cells in culture; similar plasma levels of TA-65 ® were achieved in pilot human pharmacokinetic studies with single 10- to 50-mg doses. The most striking in vivo effects were declines in the percent senescent cytotoxic (CD8 + /CD28 − ) T cells (1.5, 4.4, 8.6, and 7.5% at 3, 6, 9, and 12 months, respectively; p = not significant [N.S.], 0.018, 0.0024, 0.0062) and natural killer cells at 6 and 12 months ( p = 0.028 and 0.00013, respectively). Most of these decreases were seen in cytomegalovirus (CMV) seropositive subjects. In a subset of subjects, the distribution of telomere lengths in leukocytes at baseline and 12 months was measured. Although mean telomere length did not increase, there was a significant reduction in the percent short (<4 kbp) telomeres ( p = 0.037). No adverse events were attributed to PattonProtocol-1. We conclude that the protocol lengthens critically short telomeres and remodels the relative proportions of circulating leukocytes of CMV + subjects toward the more “youthful” profile of CMV − subjects. Controlled randomized trials are planned to assess TA-65 ® -specific effects in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
Self-citationAccelerated telomere shortening in response to life stress
Epel, E. S., Blackburn, E. H., Lin, J., Dhabhar, F. S., Adler, N. E., Morrow, J. D., & Cawthon, R. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407162101 · Cited by 3,002
Oxidative stress shortens telomeres
von Zglinicki, T. (2002) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(02)02110-2 · Cited by 2,524 · cited 1×
“In addition, stress can accelerate telomere loss by increasing cell turnover and the amount of telomeric DNA lost per cell division.(17,18) In cross-sectional studies, humans lose telomeric DNA at a very modest rate of about 15–60 bp per year, likely reflecting the small numbers of stem cells that are actively dividin…”
BackgroundAssociation between telomere length in blood and mortality in people aged 60 years or older
Cawthon, R. M., Smith, K. R., O'Brien, E., Sivatchenko, A., & Kerber, R. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12384-7 · Cited by 1,761 · cited 1×
“syndrome, cancer, and overall mortality.(18,24-25,27-30)”
Telomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Telomerase Mutations in Families with Idiopathic Pulmonary Fibrosis
Armanios, M. Y., Chen, J. J.-L., Cogan, J. D., Alder, J. K., Ingersoll, R. G., Markin, C., Lawson, W. E., Xie, M., Vulto, I., Phillips, J. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066157 · Cited by 1,357 · cited 1×
“genetic diseases with mutated telomerase, and in animal models of telomerase deficiency.(13,19-26)”
BackgroundHemann, M. T., Strong, M. A., Hao, L.-Y., & Greider, C. W. (2001) · Cell · doi:10.1016/s0092-8674(01)00504-9 · Cited by 1,219
Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age.
Vaziri, H., Dragowska, W., Allsopp, R. C., Thomas, T. E., Harley, C. B., & Lansdorp, P. M. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.21.9857 · Cited by 1,132 · cited 1×
“bp/year; p=10 and 10, respectively) are comparable to those reported previously.(43-45) Age-”
Self-citationRufer, N., Brümmendorf, T. H., Kolvraa, S., Bischoff, C., Christensen, K., Wadsworth, L., Schulzer, M., & Lansdorp, P. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.2.157 · Cited by 709 · cited 1×
“bp/year; p=10 and 10, respectively) are comparable to those reported previously.(43-45) Age-”
The rate of telomere sequence loss in human leukocytes varies with age
Frenck, R. W., Blackburn, E. H., & Shannon, K. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5607 · Cited by 675 · cited 1×
“bp/year; p=10 and 10, respectively) are comparable to those reported previously.(43-45) Age-”
Cited by
Telomeres: history, health, and hallmarks of aging
Chakravarti, D., LaBella, K. A., & DePinho, R. A. (2021) · Cell · doi:10.1016/j.cell.2020.12.028 · Cited by 637
“TA-65 (cyclastragenol) is a natural compound isolated from various plant species in the genus of Astragalus.”
BackgroundInfluentialBernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200245 · Cited by 548
“Telomerase activators have been reported (de Jesus et al, 2011; Fauce et al, 2008; Harley et al, 2011), however, their mechanism of action is still poorly understood.”
Self-citationA synopsis on aging—Theories, mechanisms and future prospects
da Costa, J. P., Vitorino, R., Silva, G. M., Vogel, C., Duarte, A. C., & Rocha-Santos, T. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.06.005 · Cited by 456
Ageing and the telomere connection: An intimate relationship with inflammation
Zhang, J., Rane, G., Dai, X., Shanmugam, M. K., Arfuso, F., Samy, R. P., Lai, M. K. P., Kappei, D., Kumar, A. P., & Sethi, G. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2015.11.006 · Cited by 386
de Jesus, B. B., Schneeberger, K., Vera, E., Tejera, A., Harley, C. B., & Blasco, M. A. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00700.x · Cited by 348
Self-citationAnti-Aging Implications of Astragalus Membranaceus (Huangqi): A Well-Known Chinese Tonic
Liu, P., Zhao, H., & Luo, Y. (2017) · Aging and disease · doi:10.14336/ad.2017.0816 · Cited by 347
Stress, cell senescence and organismal ageing
de Magalhães, J. P., & Passos, J. F. (2018) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.07.001 · Cited by 316
“One study reported that taking TA-65 may result in the decline of senescent immune system cells in patients (Harley et al., 2011).”
Telomerase at the intersection of cancer and aging
Bernardes de Jesus, B., & Blasco, M. A. (2013) · Trends in Genetics · doi:10.1016/j.tig.2013.06.007 · Cited by 227
Self-citationAssessing cell and organ senescence biomarkers
de Jesus, B. B., & Blasco, M. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247866 · Cited by 187
Self-citationElvsåshagen, T., Vera, E., Bøen, E., Bratlie, J., Andreassen, O. A., Josefsen, D., Malt, U. F., Blasco, M. A., & Boye, B. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.08.006 · Cited by 133
Self-citationTelomeres, Telomerase and Ageing
Saretzki, G. (2018) · Subcellular Biochemistry · doi:10.1007/978-981-13-2835-0_9 · Cited by 93
Aviv, A. (2020) · The FASEB Journal · doi:10.1096/fj.202001025 · Cited by 73
Novel strategies for anti-aging drug discovery
Saraswat, K., & Rizvi, S. I. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1349750 · Cited by 66
“Although mean telomere length did not increase, there was a significant reduction in the percent short telomeres [82].”
BackgroundAnti-Aging Activity and Modes of Action of Compounds from Natural Food Sources
Song, L., & Zhang, S. (2023) · Biomolecules · doi:10.3390/biom13111600 · Cited by 58
Wan, T., Weir, E. J., Johnson, M., Korolchuk, V. I., & Saretzki, G. C. (2021) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101953 · Cited by 52
“TA-65 as a highly purified extract contains at least 5% non-telomerase activator compounds (Harley et al., 2011) which could also have antioxidant capacities.”
BackgroundBennaceur, K., Atwill, M., Al Zhrany, N., Hoffmann, J., Keavney, B., Breault, D., Richardson, G., von Zglinicki, T., Saretzki, G., & Spyridopoulos, I. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.020 · Cited by 51
Disruptive chemicals, senescence and immortality
Carnero, A., Blanco-Aparicio, C., Kondoh, H., Lleonart, M. E., Martinez-Leal, J. F., Mondello, C., Scovassi, A. I., Bisson, W. H., Amedei, A., Roy, R., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv029 · Cited by 29
Ectopic expression of telomerase safely increases health span and life span
Mendelsohn, A. R., & Larrick, J. W. (2012) · Rejuvenation Research · doi:10.1089/rej.2012.1359 · Cited by 14
Therapeutic Manipulation of Ageing: Repurposing Old Dogs and Discovering New Tricks
Mallikarjun, V., & Swift, J. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.11.020 · Cited by 14
Metadata
- Authors
- Harley, C. B., Liu, W., Blasco, M., Vera, E., Andrews, W. H., Briggs, L. A., & Raffaele, J. M.
- Venue
- Rejuvenation Research
- Publisher
- SAGE Publications
- Published
- 2011-02
- Volume
- 14
- Issue
- 1
- Pages
- 45-56
- ISSN
- 1094-5458 (ISSN-L)
- 1549-1684
- 1557-8577
- OpenAlex
- W1996920927
- Cited by
- 195
- References
- 26
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.